Drug adjuvant chemotherapy after breast cancer surgery

Breast cancer is a serious impact on women's health and even life-threatening one of the most common malignant tumor in recent years, increasing incidence, second only to lung cancer as a major cause of death of women. However, the fact that the majority of patients with early breast cancer can be cured. Early discovery, timely surgery, optimization of treatment options, as well as physical and psychological concerns of patients, is to help patients eventually recover, new lease of life elements.

Surgery is currently the primary means of treatment of breast cancer, choose the appropriate drugs after chemotherapy, can significantly reduce the risk of tumor recurrence, improve the survival rate. BCIRG001 large-scale international multi-center clinical study showed that compared with traditional solutions, with Taxotere in the adjuvant chemotherapy can reduce the risk of tumor recurrence 28%, 30% lower risk of death. Meanwhile, a large number of evidence-based medical research has also been shown to docetaxel-based adjuvant chemotherapy can be effective in treating axillary lymph node positive and high-risk node-negative early breast cancer patients, thereby reducing recurrence, prolong survival time, make life quality can be improved.

 

 

Based on these findings, docetaxel has been the United States, European Union and China approved for early breast cancer adjuvant chemotherapy, and became the National Comprehensive Cancer Network (NCCN) and other authoritative guide to one of the options recommended standards. Globally, treatment with docetaxel has more than 900,000 breast cancer patients. Meanwhile, Professor Jiang Zefei also pointed out: "choose the right breast cancer after adjuvant chemotherapy drugs can indeed improve patient survival rate for patients with early breast cancer is very important to choose the best treatment plan should be to promote good medicine in front, so that patients the opportunity to get cured. " The goal of treatment is early breast cancer: radical tumor, reduce the risk of tumor recurrence and death, prolonged disease-free survival, thus prolonging the survival time. Taxotere is currently the only SFDA approved for early breast cancer adjuvant chemotherapy docetaxel.

Own particularity disease due to breast cancer, the patient will suffer from breast cancer itself and the lack of a double blow, in the rehabilitation and treatment, they will face may appear to bring pressure on tumor metastasis and treatment brought pain, these patients will give a huge psychological impact. Statistics show that breast cancer incidence in patients with mental disorders is far higher than other cancer patients, many patients after surgery for a long time, higher anxiety and depression are still there. Therefore, to help patients make the necessary psychological rehabilitation is essential. At the same time, thoroughly and treatment of early breast cancer surgery reduced the damage to the breast is extremely critical, the doctor may take chemotherapy before surgery (neoadjuvant chemotherapy), and then breast-conserving surgery, in retaining the premise of health, but also to stay live in a beautiful, two-body and mind for the patients in the future to create favorable conditions for rehabilitation.